UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Act of 1934
Date of Report (Date of earliest event reported) – April 14, 2004
IMCOR PHARMACEUTICAL CO.
(Exact name as specified in its charter)
NEVADA |
| 0-23553 |
| 62-1742885 | |
(State or other jurisdiction of |
| (Commission |
| (IRS Employer | |
|
|
|
|
| |
6175 Lusk Boulevard | 92121 | ||||
(Address of principal executive offices) | (Zip Code) | ||||
|
|
|
|
| |
(858) 410-5601 | |||||
(Registrants’ telephone number, including area code) | |||||
|
|
|
|
| |
Photogen Technologies, Inc. | |||||
(Former name or former address, if changed since last report) | |||||
Item 7. FINANCIAL STATEMENTS AND EXHIBITS.
(c) Exhibits. The following exhibits are filed with this report:
Exhibit 99(i) – Press Release of the Company, dated April 22, 2004.
2
SIGNATURES
In accordance with the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed by the undersigned hereunto duly authorized.
| IMCOR Pharmaceutical Co. | |
|
| |
|
| |
| By: /s/ Brooks Boveroux |
|
| Brooks Boveroux | |
| Chief Financial Officer | |
|
| |
Dated: April 22, 2004
3
EXHIBIT INDEX
Exhibit |
| Description |
|
|
|
Exhibit 99(i) |
| Press Release of the Company, dated April 22, 2004. |
4
